Neoplasms, Fibroepithelial: Clinical Trials

20 trials for Neoplasms, Fibroepithelial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 20 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 17, Active not recruiting 1, Recruiting 1, Terminated 1
Phase 22Active not recruiting 1, Completed 1

Follow Neoplasms, Fibroepithelial: new trials by email Literature Review of Neoplasms, Fibroepithelial trials Research Report on Neoplasms, Fibroepithelial

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
Harmonic motion imaging guided focused ultrasound (HMIgFUS), Microbubble-mediated Low Intensity Focused Ultrasound (LIFU), Microbubbles - Fibroadenoma, Breast Cancer Stage I
Phase 1RecruitingColumbia University822022-01-192026-08-13
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Phase 1 / Phase 2Active not recruitingMayo Clinic342014-04-252026-08-24
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor
Phase 1CompletedGynecologic Oncology Group202011-03-012014-12-25
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)332010-04-052019-08-09
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma
Phase 1CompletedNational Cancer Institute (NCI)4312009-10-282021-10-20
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Phase 1CompletedGynecologic Oncology Group232009-02-012014-12-31
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
adjuvant therapy, paclitaxel, carboplatin - Brenner Tumor, Fallopian Tube Cancer
Phase 1CompletedNational Cancer Institute (NCI)1132004-06-012019-07-22
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
pegfilgrastim, carboplatin, docetaxel - Fallopian Tube Cancer, Ovarian Cancer
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center2004-06-012010-09-21
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer
Phase 1CompletedNational Cancer Institute (NCI)402004-05-012019-07-22
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction - Ovarian Cancer, Primary Peritoneal Cavity Cancer
Phase 1CompletedMayo Clinic372004-04-192024-01-16
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer
Phase 1CompletedNational Cancer Institute (NCI)2003-07-012015-04-30
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Carboplatin, Paclitaxel Poliglumex, Pharmacological Study - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
Phase 1CompletedGynecologic Oncology Group322003-04-012015-05-08
Immunotoxin Therapy in Treating Patients With Advanced Cancer
SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer
Phase 1CompletedNational Cancer Institute (NCI)2000-12-012015-04-30
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
carboplatin, paclitaxel, topotecan hydrochloride - Ovarian Cancer, Primary Peritoneal Cavity Cancer
Phase 1CompletedGynecologic Oncology Group2000-02-012013-05-27
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
etoposide, topotecan hydrochloride - Fallopian Tube Cancer, Ovarian Cancer
Phase 1CompletedGynecologic Oncology Group241999-09-012013-05-27
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer
Phase 1CompletedGynecologic Oncology Group481999-03-012013-05-27
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
etoposide, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer
Phase 1TerminatedGynecologic Oncology Group1998-05-012013-06-10
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission
filgrastim, melphalan, thiotepa - Ovarian Cancer
Phase 1CompletedFred Hutchinson Cancer Center451997-01-012010-09-15
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
paclitaxel, cisplatin, topotecan hydrochloride - Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)301996-12-012013-01-24
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
carboplatin, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer
Phase 1CompletedGynecologic Oncology Group2013-07-09

Narrower conditions

Brenner Tumor (19)  ·  Ovarian Neoplasms (16)  ·  Fallopian Tube Neoplasms (15)  ·  Carcinoma, Ovarian Epithelial (13)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Head and Neck Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Mesothelioma, Malignant (2)  ·  Pancreatic Neoplasms (2)  ·  Salivary Gland Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Uterine Cervical Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Fibroadenoma (1)  ·  Neurotoxicity Syndromes (1)

Broader conditions

Neoplasms (20)  ·  Neoplasms by Histologic Type (20)  ·  Neoplasms by Site (20)  ·  Neoplasms, Connective Tissue (20)  ·  Neoplasms, Connective and Soft Tissue (20)  ·  Neoplasms, Fibrous Tissue (20)  ·  Neoplasms, Glandular and Epithelial (20)  ·  Adnexal Diseases (19)  ·  Endocrine Gland Neoplasms (19)  ·  Endocrine System Diseases (19)  ·  Female Urogenital Diseases (19)  ·  Female Urogenital Diseases and Pregnancy Complications (19)  ·  Genital Diseases (19)  ·  Genital Diseases, Female (19)

Interventions

Carboplatin (9)  ·  Paclitaxel (8)  ·  Taxes (6)  ·  Bevacizumab (3)  ·  Cisplatin (3)  ·  Topotecan (3)  ·  Docetaxel (2)  ·  Etoposide (2)  ·  Filgrastim (2)  ·  SS1(dsFv)PE38 (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  Bortezomib (1)  ·  Chemotherapy, Adjuvant (1)  ·  Disulfides (1)  ·  Erlotinib Hydrochloride (1)

Sponsors

Gynecologic Oncology Group (8)  ·  National Cancer Institute (NCI) (7)  ·  Fred Hutchinson Cancer Center (2)  ·  Mayo Clinic (2)  ·  Columbia University (1)

Countries

United States (19)  ·  Canada (2)  ·  Japan (1)  ·  Norway (1)

Top investigators

Peter G. Rose, MD (3)  ·  Don Dizon (2)  ·  Evanthia Galanis, MD (2)  ·  Leona A. Holmberg, MD, PhD (2)  ·  Mark Morgan (2)  ·  Bradley Monk (1)  ·  Bret Taback, MD (1)  ·  Dan Veljovich, MD (1)  ·  Deborah Armstrong (1)  ·  Joan Walker (1)  ·  Katherine M Bell-McGuinn (1)  ·  Michael A. Bookman, MD (1)  ·  Michael Rodriguez, MD (1)  ·  Raffit Hassan, MD (1)  ·  Robert Kreitman, MD (1)

Results publications

PMID 16412499, PMID 16631245, PMID 16959305, PMID 19671873, PMID 28341300, PMID 31708167, PMID 33610319

NIH funding

U10CA027469 (8), P50CA136393 (2), U10CA180868 (2), P30CA015083 (1), R01CA136547 (1), R01CA200507 (1), R01CA228275 (1), R01CA301199 (1)